Clinical Trials | December 11, 2025
Lilly drug cuts risk of disease progression or death by 80% in trial
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The company has unveiled the results of pirtobrutinib from its BRUIN CLL-313 study
The Phase 2 study tested two dose levels of pumitamig alongside four standard chemotherapy regimens across first
Acetaminophen Injection is indicated for the management of mild to moderate pain in adult and pediatric patients 2 years and older
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Captured microbes are then neutralized on engineered microbicidal surfaces
DUPLEX’s two-compartment, PVC- and DEHP-free design keeps medication and diluent separate until activation
It's an acquisition that aims at forming one of the US's largest oncology trial networks
VitiPure serves as essential solubilizers, emulsifiers, and bioavailability enhancers in drug formulations
Excelsior aims to make reshoring affordable and strategic, shielding nations from geopolitical disruptions
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Subscribe To Our Newsletter & Stay Updated
